Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer

MERTK and AXL are members of the TAM family of receptor tyrosine kinases and are abnormally expressed in 69% and 93% of non-small cell lung cancers (NSCLCs), respectively. Expression of MERTK and/or AXL provides a survival advantage for NSCLC cells and correlates with lymph node metastasis, drug res...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dan Yan, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	MERTK AXL TAM family receptor tyrosine kinase targeted therapy NSCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f008783afb8b4deca24ca6395ea261cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f008783afb8b4deca24ca6395ea261cc
record_format	dspace
spelling	oai:doaj.org-article:f008783afb8b4deca24ca6395ea261cc2021-11-25T17:01:57ZTargeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer10.3390/cancers132256392072-6694https://doaj.org/article/f008783afb8b4deca24ca6395ea261cc2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5639https://doaj.org/toc/2072-6694MERTK and AXL are members of the TAM family of receptor tyrosine kinases and are abnormally expressed in 69% and 93% of non-small cell lung cancers (NSCLCs), respectively. Expression of MERTK and/or AXL provides a survival advantage for NSCLC cells and correlates with lymph node metastasis, drug resistance, and disease progression in patients with NSCLC. The TAM receptors on host tumor infiltrating cells also play important roles in the immunosuppressive tumor microenvironment. Thus, MERTK and AXL are attractive biologic targets for NSCLC treatment. Here, we will review physiologic and oncologic roles for MERTK and AXL with an emphasis on the potential to target these kinases in NSCLCs with activating EGFR mutations.Dan YanH. Shelton EarpDeborah DeRyckereDouglas K. GrahamMDPI AGarticleMERTKAXLTAM familyreceptor tyrosine kinasetargeted therapyNSCLCNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5639, p 5639 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	MERTK AXL TAM family receptor tyrosine kinase targeted therapy NSCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	MERTK AXL TAM family receptor tyrosine kinase targeted therapy NSCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Dan Yan H. Shelton Earp Deborah DeRyckere Douglas K. Graham Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
description	MERTK and AXL are members of the TAM family of receptor tyrosine kinases and are abnormally expressed in 69% and 93% of non-small cell lung cancers (NSCLCs), respectively. Expression of MERTK and/or AXL provides a survival advantage for NSCLC cells and correlates with lymph node metastasis, drug resistance, and disease progression in patients with NSCLC. The TAM receptors on host tumor infiltrating cells also play important roles in the immunosuppressive tumor microenvironment. Thus, MERTK and AXL are attractive biologic targets for NSCLC treatment. Here, we will review physiologic and oncologic roles for MERTK and AXL with an emphasis on the potential to target these kinases in NSCLCs with activating EGFR mutations.
format	article
author	Dan Yan H. Shelton Earp Deborah DeRyckere Douglas K. Graham
author_facet	Dan Yan H. Shelton Earp Deborah DeRyckere Douglas K. Graham
author_sort	Dan Yan
title	Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
title_short	Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
title_full	Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
title_fullStr	Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
title_full_unstemmed	Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
title_sort	targeting mertk and axl in <i>egfr</i> mutant non-small cell lung cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f008783afb8b4deca24ca6395ea261cc
work_keys_str_mv	AT danyan targetingmertkandaxliniegfrimutantnonsmallcelllungcancer AT hsheltonearp targetingmertkandaxliniegfrimutantnonsmallcelllungcancer AT deborahderyckere targetingmertkandaxliniegfrimutantnonsmallcelllungcancer AT douglaskgraham targetingmertkandaxliniegfrimutantnonsmallcelllungcancer
_version_	1718412811913134080

Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer

Ejemplares similares